Integrating immunotherapy into chemoradiation regimens for medically inoperable locally advanced non-small cell lung cancer

被引：14

作者：

Jabbour, Salma K. ^{[1
]}

Berman, Abigail T. ^{[2
]}

Simone, Charles B., II ^{[3
]}

机构：

[1] Rutgers State Univ, Rutgers Robert Wood Johnson Med Sch, Rutgers Canc Inst New Jersey, Dept Radiat Oncol, New Brunswick, NJ USA

[2] Hosp Univ Penn, Dept Radiat Oncol, Perelman Sch Med, 3400 Spruce St, Philadelphia, PA 19104 USA

[3] Univ Maryland, Sch Med, Dept Radiat Oncol, Baltimore, MD 21201 USA

来源：

TRANSLATIONAL LUNG CANCER RESEARCH | 2017年 / 6卷 / 02期

关键词：

Immunotherapy; chemoradiation; non-small cell lung cancer (NSCLC); PD-1; PD-L1; TELOMERASE PEPTIDE VACCINATION; PHASE-III TRIAL; RADIATION-THERAPY; T-CELLS; RADIOTHERAPY; TUMOR; CONSOLIDATION; CONCURRENT; CHEMOTHERAPY; TECEMOTIDE;

D O I：

10.21037/tlcr.2017.04.02

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

For patients with inoperable stage II-III non-small cell lung cancer (NSCLC), the backbone of curative intent therapy is concurrent chemoradiotherapy (CRT). As checkpoint inhibitors have shown clinical benefit in the setting of metastatic NSCLC, additional study is necessary to understand their role in patients receiving CRT. When integrating immunotherapy with radiotherapy (RT) for cure, clinicians will need to consider synergy, timing, doses, and safety among the combination of therapies. This article seeks to review data evaluating interactions, temporal sequencing, fractionation, and overlapping toxicity profiles of thoracic chemoradiation and immunotherapy.

引用

页码：113 / 118

页数：6

共 46 条

[1] Immunotherapy in locally-advanced non-small cell lung cancer: releasing the brakes on consolidation? [J].

Berman, Abigail T. ;

Simone, Charles B., II .

TRANSLATIONAL LUNG CANCER RESEARCH, 2016, 5 (01) :138-142

[2] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].

Borghaei, H. ;

Paz-Ares, L. ;

Horn, L. ;

Spigel, D. R. ;

Steins, M. ;

Ready, N. E. ;

Chow, L. Q. ;

Vokes, E. E. ;

Felip, E. ;

Holgado, E. ;

Barlesi, F. ;

Kohlhaeufl, M. ;

Arrieta, O. ;

Burgio, M. A. ;

Fayette, J. ;

Lena, H. ;

Poddubskaya, E. ;

Gerber, D. E. ;

Gettinger, S. N. ;

Rudin, C. M. ;

Rizvi, N. ;

Crino, L. ;

Blumenschein, G. R. ;

Antonia, S. J. ;

Dorange, C. ;

Harbison, C. T. ;

Finckenstein, F. Graf ;

Brahmer, J. R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639

[3] Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study [J].

Bradley, Jeffrey D. ;

Paulus, Rebecca ;

Komaki, Ritsuko ;

Masters, Gregory ;

Blumenschein, George ;

Schild, Steven ;

Bogart, Jeffrey ;

Hu, Chen ;

Forster, Kenneth ;

Magliocco, Anthony ;

Kavadi, Vivek ;

Garces, Yolanda I. ;

Narayan, Samir ;

Iyengar, Puneeth ;

Robinson, Cliff ;

Wynn, Raymond B. ;

Koprowski, Christopher ;

Meng, Joanne ;

Beitler, Jonathan ;

Gaur, Rakesh ;

Curran, Walter, Jr. ;

Choy, Hak .

LANCET ONCOLOGY, 2015, 16 (02) :187-199

[4] Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer [J].

Brahmer, Julie ;

Reckamp, Karen L. ;

Baas, Paul ;

Crino, Lucio ;

Eberhardt, Wilfried E. E. ;

Poddubskaya, Elena ;

Antonia, Scott ;

Pluzanski, Adam ;

Vokes, Everett E. ;

Holgado, Esther ;

Waterhouse, David ;

Ready, Neal ;

Gainor, Justin ;

Aren Frontera, Osvaldo ;

Havel, Libor ;

Steins, Martin ;

Garassino, Marina C. ;

Aerts, Joachim G. ;

Domine, Manuel ;

Paz-Ares, Luis ;

Reck, Martin ;

Baudelet, Christine ;

Harbison, Christopher T. ;

Lestini, Brian ;

Spigel, David R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (02) :123-135

[5] Telomerase Peptide Vaccination in NSCLC: A Phase II Trial in Stage III Patients Vaccinated after Chemoradiotherapy and an 8-Year Update on a Phase I/II Trial [J].

Brunsvig, Paal Fr. ;

Kyte, Jon Amund ;

Kersten, Christian ;

Sundstrum, Stein ;

Muller, Mona ;

Nyakas, Marta ;

Hansen, Gaute L. ;

Gaudernack, Gustav ;

Aamdal, Steinar .

CLINICAL CANCER RESEARCH, 2011, 17 (21) :6847-6857

[6] Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial [J].

Butts, Charles ;

Socinski, Mark A. ;

Mitchell, Paul L. ;

Thatcher, Nick ;

Havel, Libor ;

Krzakowski, Maciej ;

Nawrocki, Sergiusz ;

Ciuleanu, Tudor-Eliade ;

Bosquee, Lionel ;

Manuel Trigo, Jose ;

Spira, Alexander ;

Tremblay, Lise ;

Nyman, Jan ;

Ramlau, Rodryg ;

Wickart-Johansson, Gun ;

Ellis, Peter ;

Gladkov, Oleg ;

Pereira, Jose Rodrigues ;

Eberhardt, Wilfried Ernst Erich ;

Helwig, Christoph ;

Schroeder, Andreas ;

Shepherd, Frances A. .

LANCET ONCOLOGY, 2014, 15 (01) :59-68

[7] Sequential vs Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer: Randomized Phase III Trial RTOG 9410 [J].

Curran, Walter J., Jr. ;

Paulus, Rebecca ;

Langer, Corey J. ;

Komaki, Ritsuko ;

Lee, Jin S. ;

Hauser, Stephen ;

Movsas, Benjamin ;

Wasserman, Todd ;

Rosenthal, Seth A. ;

Gore, Elizabeth ;

Machtay, Mitchell ;

Sause, William ;

Cox, James D. .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2011, 103 (19) :1452-1460

[8] Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated [J].

Demaria, S ;

Ng, B ;

Devitt, ML ;

Babb, JS ;

Kawashima, N ;

Liebes, L ;

Formenti, SC .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 58 (03) :862-870

[9] Radiation as an immunological adjuvant: current evidence on dose and fractionation [J].

Demaria, Sandra ;

Formenti, Silvia C. .

FRONTIERS IN ONCOLOGY, 2012, 2

[10] Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice [J].

Deng, Liufu ;

Liang, Hua ;

Burnette, Byron ;

Beckett, Michael ;

Darga, Thomas ;

Weichselbaum, Ralph R. ;

Fu, Yang-Xin .

JOURNAL OF CLINICAL INVESTIGATION, 2014, 124 (02) :687-695

← 1 2 3 4 5 →